



LIFEVISION HEALTHCARE
Plot No. 138-142, EPIP, Phase-1, Jharmajri,
Baddi, Distt.: Solan (H.P.)-174103

Page
01 of 01

DEPARTMENT: QUALITY CONTROL

**CERTIFICATE OF ANALYSIS
(FINISHED PRODUCT)**

Product Name	NAUXIN		
Generic Name	Doxylamine Succinate, Pyridoxine Hydrochloride & Folic Acid Tablets		
Batch No.	LTA - 54859	A.R.No.	QC/FP/LTA - 54859
Mfg. Date	JUL. 2026	Batch Size	50,000 Tablets
Exp. Date	JUN. 2028	Sample Quantity	100 Tablets
Date of Receipt	13-07-2026	Date of Release	15-07-2026
Date of Analysis	14-07-2026	Mfg. Lic. No.	MNB/09/804 & MB/09/805
Marketed By	MYGEN PHARMA LLP		

S. No.	TEST	SPECIFICATION	OBSERVATION												
1	Description	Brown coloured, oval shaped, biconvex, with break line on one side and plain on other side, film coated tablets.	Brown coloured, oval shaped, biconvex, with break line on one side and plain on other side, film coated tablets.												
2	Identification Doxylamine Succinate USP Folic Acid IP Pyridoxine Hydrochloride IP	In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution.	In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution.												
3	Average weight	280 mg $\pm$ 7.5 %	284.66 mg												
4	Uniformity of weight	$\pm$ 7.5 % of average weight	-1.95 % to + 1.80 %												
5	Disintegration Test	Not more than 30 minutes	09 minutes 07 seconds												
6	Physical Parameters: Length Thickness Width Hardness	11.60 mm $\pm$ 0.3 mm 4.30 mm $\pm$ 0.3 mm 7.05 mm $\pm$ 0.3 mm Not less than 4.0 Kg/cm ²	11.59 mm to 11.68 mm 4.29 mm to 4.38 mm 7.03 mm to 7.12 mm 4.5 Kg/cm ² to 5.5 Kg/cm ²												
7	Assay	Each film coated tablet contains: <table> <tr> <td>Doxylamine Succinate USP</td> <td>20 mg</td> <td>18.0 mg to 22.0 mg (90.0 % to 110.0 %)</td> <td>19.892 mg (99.46 %)</td> </tr> <tr> <td>Pyridoxine Hydrochloride IP</td> <td>20 mg</td> <td>N.L.T. 18.0 mg (N.L.T. 90.0 %)</td> <td>21.854 mg (109.27 %)</td> </tr> <tr> <td>Folic Acid IP</td> <td>5 mg</td> <td>N.L.T. 4.50 mg (N.L.T. 90.0 %)</td> <td>5.792 mg (115.84 %)</td> </tr> </table>		Doxylamine Succinate USP	20 mg	18.0 mg to 22.0 mg (90.0 % to 110.0 %)	19.892 mg (99.46 %)	Pyridoxine Hydrochloride IP	20 mg	N.L.T. 18.0 mg (N.L.T. 90.0 %)	21.854 mg (109.27 %)	Folic Acid IP	5 mg	N.L.T. 4.50 mg (N.L.T. 90.0 %)	5.792 mg (115.84 %)
Doxylamine Succinate USP	20 mg	18.0 mg to 22.0 mg (90.0 % to 110.0 %)	19.892 mg (99.46 %)												
Pyridoxine Hydrochloride IP	20 mg	N.L.T. 18.0 mg (N.L.T. 90.0 %)	21.854 mg (109.27 %)												
Folic Acid IP	5 mg	N.L.T. 4.50 mg (N.L.T. 90.0 %)	5.792 mg (115.84 %)												

Remark: The above finished product complies to as per In House specification

	Prepared by Officer-QC	Checked by Executive-QC	Approved by Manager-QC
Signature			
Date	15-07-2026	15-07-2026	15-07-2026